Plasmodium Patents (Class 424/268.1)
-
Patent number: 7332595Abstract: The invention discloses isolated DNA sequences encoded by polypeptides characterized by the presence in their structure of one or more sequences bearing all or part of one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of P. falciparum in hepatic cells.Type: GrantFiled: July 10, 2001Date of Patent: February 19, 2008Assignee: Institut PasteurInventors: Claudine Guerin-Marchand, Pierre Druilhe
-
Patent number: 7306806Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: January 25, 2002Date of Patent: December 11, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
-
Patent number: 7256281Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: April 1, 2003Date of Patent: August 14, 2007Assignees: United States of America as represented by the Secretary of the ArmyInventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
-
Patent number: 7198791Abstract: The invention presents vaccine formulations comprising highly antigenic epitopes identified within the semi-conserved loop-I of domain III that are capable of eliciting parasite growth inhibitory antibodies. The cyclized or linear peptides can be applied by known adjuvants or be encapsulated by or attached onto the surface of liposomes or virosomes (IRIVs) which serve as human compatible antigen delivery systems. Both cyclized and linear versions of the peptide antigens are surprisingly effective in eliciting immune responses that are cross-reactive with parasite-expressed AMA-1.Type: GrantFiled: March 3, 2003Date of Patent: April 3, 2007Assignee: Pluschke, Gerd et al.Inventors: Gerd Pluschke, Mueller Markus, John Robinson, Rinaldo Zurbriggen, Annabelle Freund-Renard
-
Patent number: 7179615Abstract: The present invention relates generally to a method for the prophylaxis and treatment of parasitic infections in animals and birds. More particularly, the present invention contemplates a method for the prophylaxis and treatment of Plasmodium infection in mammals and the prophylaxis and treatment of disease conditions caused or exacerbated by Plasmodium. Even more particularly, the present invention is directed to a method for the prophylaxis and treatment of malaria including ameliorating the clinical effects of malaria and agents useful for same.Type: GrantFiled: July 29, 1998Date of Patent: February 20, 2007Assignees: Menzies School of Health Research, Duke UniversityInventors: Nicholas Mark Anstey, Joseph Brice Weinberg, Donald L. Granger
-
Patent number: 7125958Abstract: The present invention relates to carbohydrates capable of acting as receptors for malaria antigens present on the surfaces of malaria infected erythrocytes. The receptors according to the invention comprises negatively charged glycosaminoglycan-like moities, preferably sulphated. The invention also relates to novel malaria polypeptides capable of acting as ligands in relation to the receptors according to the invention. The invention also encompasses the use thereof as medicaments, pharmaceutical compositions containing the same as well as antibodies directed against said new ligands.Type: GrantFiled: September 18, 1998Date of Patent: October 24, 2006Assignee: Karolinska Innovations ABInventors: Mats Wahlgren, Antonio Barragan, Johan Carlson, Chen Qijun, Victor Fernandez
-
Patent number: 7101556Abstract: The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1/MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.Type: GrantFiled: February 1, 2002Date of Patent: September 5, 2006Assignee: Second Military Medical UniversityInventor: Weiqing Pan
-
Patent number: 7087231Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.Type: GrantFiled: April 19, 2001Date of Patent: August 8, 2006Assignee: Institut PasteurInventors: Claudine Guerin-Marchand, Pierre Druilhe
-
Patent number: 7078043Abstract: A non-naturally occurring variant of a C-terminal fragment of a Plasmodium merozoite surface protein-1 (MSP-1) wherein said variant has (i) a reduced affinity, compared with a naturally occurring Plasmodium MSP-119, for at least one first antibody capable of blocking the binding of a second antibody, which second antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 and (ii) substantially the same affinity for at least one third antibody compared with said naturally occurring Plasmodium MSP-119. which third antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 is provided for use in an anti-malarial vaccine.Type: GrantFiled: October 16, 2001Date of Patent: July 18, 2006Assignee: Medical Research CouncilInventors: Anthony Holder, Berry Birdsall, James Feeney, William Morgan, Shabih Syed, Chairat Uthaipibull
-
Patent number: 7078507Abstract: Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.Type: GrantFiled: November 12, 2002Date of Patent: July 18, 2006Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: David Narum, Hong Liang, Steve Fuhrmann, B. Kim Lee Sim
-
Patent number: 7071296Abstract: The present invention relates to immunogenic compositions comprising as an immunogen a long synthetic or recombinant peptide of a merozoite surface protein 3b (MSP-3b) peptide, an MSP-3c peptide and a MSP-3d peptide. Vaccines against malaria are also disclosed using these peptides alone or in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: February 10, 2004Date of Patent: July 4, 2006Assignee: Institut PasteurInventor: Pierre Druilhe
-
Patent number: 7067315Abstract: The present invention provides novel assay systems and methods for monitoring cell invasion by protozoal parasites. The present invention further provides methods of using these assays systems to identify compounds that treat or prevent protozoal infection. The present invention further provides pharmaceutical compositions that have anit-protozoal activity and methods of treating infections.Type: GrantFiled: May 22, 2002Date of Patent: June 27, 2006Assignees: President and Fellows of Harvard College, University of VermontInventors: Nicholas J. Westwood, Gary E. Ward, Kimberly L. Carey, Timothy J. Mitchinson
-
Patent number: 7060276Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: March 25, 2002Date of Patent: June 13, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
-
Patent number: 7056518Abstract: Polypeptide molecules containing at least 10 consecutive amino acids of the amino acid sequence shown in FIG. 2, representing the LSA3 antigen, the following peptides being excluded: RDELFNELLNSVDVNGEVKENILEESQVNDDIFNSLVKSVQQEQQHNVEE VEESVEENDEESVEENVEENVENNDDGSVASSVEESIASSVDESIDSSIE- ENVAPTVEEIVAPTVEEIVAPSVVEKCAPSVEESVAPSVEESVAEMLKER (729S) RDELFNELLNSVDVNGEVKENILEESQVNDDIFNSLVKSVQQEQQHN DELFNELLNSVDVNGEVKENILEESQ, (NRI) LEESQVNDDIFSNSLVKSVQQEQQHNV, (NRII) VESVAPSVEESVAPSVEESVAENVESSV.Type: GrantFiled: December 22, 2000Date of Patent: June 6, 2006Assignee: Institut PasteurInventors: Pierre Druilhe, Pierre Daubersies
-
Patent number: 7029685Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.Type: GrantFiled: October 15, 2002Date of Patent: April 18, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
-
Patent number: 7029678Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: September 3, 2003Date of Patent: April 18, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 6942866Abstract: A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that contains an immunogen for inducing the production of antibodies to malarial proteins. An immunogenic malarial epitope is expressed between residues 78 and 79 of the HBc immunogenic loop sequence. The chimer preferably contains a malaria-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.Type: GrantFiled: August 15, 2001Date of Patent: September 13, 2005Assignee: Apovia, Inc.Inventor: Ashley J. Birkett
-
Patent number: 6855322Abstract: This application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: January 25, 2002Date of Patent: February 15, 2005Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jeffrey A. Lyon, Evelina Angov
-
Patent number: 6815183Abstract: The present invention is directed to isolated nucleic acid molecules encoding Plasmodium sp. chitinases. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of the chitinase in host cells. The invention further provides methods of screening a substance for the ability of the substance to modify chitinase function, and a method for isolating other chitinase molecules. DNA oligomers capable of hybridizing to the nucleic acid molecule encoding the chitinase are provided, which can be used to detect chitinase in a sample. An isolated Plasmodium sp. chitinase is also provided. Antibodies specific for the chitinase, and fragments thereof, are provided, as are compositions comprising the chitinase and a compatible carrier. The subject invention further provides methods of preventing infection of mosquitoes by Plasmodium sp. and methods of preventing transmission of malaria.Type: GrantFiled: May 26, 2000Date of Patent: November 9, 2004Assignee: The Board of Regents of the University of Texas SystemInventor: Joseph M. Vinetz
-
Patent number: 6783765Abstract: The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.Type: GrantFiled: March 23, 2001Date of Patent: August 31, 2004Assignee: Council of Scientific and Industrial ResearchInventors: Javed Naim Agrewala, Naresh Sharma
-
Patent number: 6780417Abstract: The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of Plasmodium falciparum, Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.Type: GrantFiled: March 2, 1995Date of Patent: August 24, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David C. Kaslow, Stuart Isaacs, Bernard Moss
-
Publication number: 20040096466Abstract: The present invention relates to novel preparations for a broad-spectrum antiplasmodial vaccine that may contain a vaccinating antigen of Plasmodium falciparum capable of inducing resistance to the parasite and a kit containing the same. The invention relates to a method that may invoke the mechanisms of protective immunity and/or premonition.Type: ApplicationFiled: September 11, 2002Publication date: May 20, 2004Applicant: INSTITUT PASTEURInventors: Pierre Druilhe, Hasnaq Bouharoun-Tayoun, Claude Oeuvray
-
Patent number: 6623739Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.Type: GrantFiled: February 24, 2000Date of Patent: September 23, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Publication number: 20030138454Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. There is also provided a method of inducing a CD4+ T-cell response against a target antigen, by administering a composition comprising a source of one or more CD4+ T cell epitopes of the target antigen wherein the source of CD4+ epitopes is a non-replicating or replication impaired recombinant poxvirus vector. A method of inducing a combined CD4+ and CD8+ T cell response against a target antigen is also described herein.Type: ApplicationFiled: February 19, 2002Publication date: July 24, 2003Applicant: Oxxon Pharmaccines, Ltd.Inventors: Adrian V. S. Hill, Helen McShane, Sarah C. Gilbert, William Reece, Joerg Schneider
-
Patent number: 6593463Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.Type: GrantFiled: October 20, 1998Date of Patent: July 15, 2003Assignee: Genzyme Transgenics CorporationInventors: Li How Chen, Harry Meade
-
Publication number: 20030064075Abstract: The invention discloses a molecule or polypeptide composition characterized by the presence in its structure of one or more peptide sequences bearing all or part of one or more T epitopes, and possibly other epitopes, particularly B epitopes, charactistic of proteins resulting from the infectious activity of P. falciparum in hepatic cells. Also disclosed is the use of these molecules in tests, and a set or kits for in vitro diagnosis of paludism from a biological sample from the individual in whom the disease is to be detected. The use of these molecules in compositions for paludism vaccines is also covered.Type: ApplicationFiled: July 10, 2001Publication date: April 3, 2003Inventors: Claudine Guerin-Marchand, Pierre Druilhe
-
Publication number: 20030049278Abstract: The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of Plasmodium falciparum, Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.Type: ApplicationFiled: March 2, 1995Publication date: March 13, 2003Inventors: DAVID C. KASLOW, STUART ISAACS, BERNARD MOSS
-
Publication number: 20030026807Abstract: The invention is directed to improved immunopotentiating systems for preparation of immunogenic materials. More particularly, the invention is directed to immunogenic compositions containing a protein, polypeptide, or peptide, a hydrophobic anchor, and a proteosome. The immunogenic compositions are suitable for use as therapeutic agents and vaccines.Type: ApplicationFiled: December 2, 1997Publication date: February 6, 2003Inventor: GEORGE H. LOWELL
-
Patent number: 6491920Abstract: Proteins from the merozoite stage of the malaria parasite, fragments and derivatives thereof, DNA coding for the said proteins, and processes for the preparation of the proteins and plasmid and viral vectors useful in said processes. The invention also provides antibodies to the proteins and immunological compositions containing the proteins.Type: GrantFiled: May 24, 1999Date of Patent: December 10, 2002Assignee: Imperial College Innovations LimitedInventors: Kathryn Jane Hallowes Robson, Jennifer Ruth Sadler Hall
-
Publication number: 20020127241Abstract: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.Type: ApplicationFiled: August 7, 2001Publication date: September 12, 2002Inventors: David L. Narum, Kim L. Sim
-
Patent number: 6420523Abstract: The present invention provides compositions of matter comprising a polypeptide expressed from insect cells harboring a baculovirus vector the encodes the polypeptide, wherein the polypeptide comprises amino acid sequences derived from the p42 fragment of the Plasmodium falciparum gp 195 protein or derivatives thereof. Such compositions of matter find use for example for inducing the production of anti-p42 antibodies both in vivo and in vitro.Type: GrantFiled: February 14, 1994Date of Patent: July 16, 2002Assignee: University of HawaiiInventors: Sandra Chang, George S. N. Hui, Philip J. Barr, Helen Gibson
-
Patent number: 6417341Abstract: An immunogenic polypeptide for use in inducing an immune response against Plasmodium infection comprises an amino acid sequence corresponding to a non-full length fragment of the apical membrane antigen 1 (AMA-1) of Plasmodium species which does not include a transmembrane domain thereof, and which is stabilised by folding thereof. Production of the immunogenic polypeptide by expression of a recombinant DNA molecule in a host cell, and methods and compositions using the immunogenic polypeptide are disclosed.Type: GrantFiled: October 7, 1996Date of Patent: July 9, 2002Assignee: Saramane Pty., Ltd.Inventors: Robin Fredric Anders, Pauline Elizabeth Crewther, Mary Shu Mai Leet, Anthony Neil Hodder, David Pye
-
Publication number: 20020009467Abstract: This invention provides antigen substance inductors which produce highly selective and/or specific vaccine precursor, vaccine, antibody (including idiotype antibody), neutralizing antibody, antitoxin.Type: ApplicationFiled: June 18, 2001Publication date: January 24, 2002Inventors: Shozo Koyama, Satoshi Tanaka
-
Patent number: 6333406Abstract: A Plasmodium falciparum gene encoding immunogenic SERA protein has been isolated by a) systematically screening a lambda gt11 recombinant DNA expression library with a murine monoclonal antibody directed against protein antigens of this pathogen, and b) systematically screening a lambda gt11 genomic cDNA and oligonucleotide probes directed against this pathogen. A 111 kDa protein has been shown to have immunogenic activity against parasite inhibitory antibodies. The gene encoding this protein, including the signal sequence and regulatory sequence in the adjacent 5′ flanking sequence has been isolated and sequenced. Isolation and characterization of genes encoding major protein antigens of P. falciparum make it possible to develop reagents useful in the diagnosis, prevention and treatment of malaria. In addition, the signal sequences or regulatory sequences of this gene can be used to stimulate the production of other useful genetic products.Type: GrantFiled: March 14, 1994Date of Patent: December 25, 2001Inventors: Joseph W. Inselburg, David J. Bzik, Toshihiro Horii, Tomohiko Sugiyama
-
Patent number: 6319502Abstract: The invention discloses a molecule or polypeptide composition characterized by the presence in its structure of one or more peptide sequences bearing all or part of one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of P. falciparum in hepatic cells.Type: GrantFiled: June 5, 1995Date of Patent: November 20, 2001Assignee: Institut PasteurInventors: Claudine Guerin-Marchand, Pierre Druilhe
-
Patent number: 6316000Abstract: Compositions comprising biologically pure Pfs230 and nucleic acids which encode them are provided. The proteins can be used induce transmission blocking immune responses in susceptible hosts.Type: GrantFiled: October 20, 1997Date of Patent: November 13, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kim C. Williamson, David C. Kaslow
-
Patent number: 6270771Abstract: The invention discloses a molecule or polypeptide composition characterized by the presence in its structure of one or more peptide sequences bearing all or part of one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of P. Falciparum in hepatic cells. Also disclosed is the use of these molecules in tests, and a kit for in vitro diagnosis of paludism from a biological sample from the individual in whom the disease is to be detected.Type: GrantFiled: November 24, 1993Date of Patent: August 7, 2001Assignee: Institut PasteurInventors: Claudine Guerin-Marchand, Pierre Druilhe
-
Patent number: 6214353Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: May 21, 1998Date of Patent: April 10, 2001Assignees: Pasteur Merieux Serums et Vaccins, The University of HawaiiInventors: Enzo Paoletti, Charles de Taisne, Sandra Chang, George Hui, Wasim A. Siddigui